Congress Asset Management’s Janux Therapeutics JANX Stock Holding History

Congress Asset Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.46M	Buy	84,211 +16,601	+25%	+$279K	0.01%	311
2026 Q2	$1.04M	Buy	67,610 +743	+1%	+$10.8K	0.01%	304
2026 Q1	$929K	Buy	66,867 +9,525	+17%	+$131K	0.01%	343
2025 Q4	$791K	Buy	57,342 +1,569	+3%	+$36.9K	0.01%	324
2025 Q3	$1.36M	Buy	+55,773	New	+$1.36M	0.01%	304

Other funds holding JANX

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MAM

Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Congress Asset Management's JANX Position: Q3 2026 in Review

Congress Asset Management increased its Janux Therapeutics (JANX) stake by 25% in Q3 2026, buying an estimated $279K and bringing the position to 84,211 shares worth $1.46M. The position accounts for 0.01% of the portfolio, ranked #311.

Congress Asset Management first reported a position in JANX in Q3 2025 and has held it in 5 quarters since. 6 funds tracked by Wall St. Rank hold JANX as of Q3 2026.

Congress Asset Management held 84,211 shares of Janux Therapeutics worth $1.46M as of Q3 2026.
Congress Asset Management bought 16,601 Janux Therapeutics shares in Q3 2026, an estimated $279K.
Janux Therapeutics made up 0.01% of Congress Asset Management's portfolio in Q3 2026, its #311 holding.
Congress Asset Management first reported a position in Janux Therapeutics in Q3 2025 and has held it in 5 quarters since.
6 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2026.

Based on Congress Asset Management's 13F filing for Q3 2026, filed 6 Oct 2026.